184 related articles for article (PubMed ID: 35071007)
41. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
42. Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a
Varasteh Z; Mohanta S; Robu S; Braeuer M; Li Y; Omidvari N; Topping G; Sun T; Nekolla SG; Richter A; Weber C; Habenicht A; Haberkorn UA; Weber WA
J Nucl Med; 2019 Dec; 60(12):1743-1749. PubMed ID: 31405922
[TBL] [Abstract][Full Text] [Related]
43. Molecular Imaging of Fibroblast Activation in Rabbit Atherosclerotic Plaques: a Preclinical PET/CT Study.
Ji T; Zan C; Li L; Cao J; Su Y; Wang H; Wu Z; Yang MF; Dou K; Li S
Mol Imaging Biol; 2024 Apr; ():. PubMed ID: 38664355
[TBL] [Abstract][Full Text] [Related]
44. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M
J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750
[TBL] [Abstract][Full Text] [Related]
45. Syntheses and Preliminary Evaluation of Dual Target PET Probe [18F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer.
Chen Z; Fu H; Wu H; Huang J; Yao L; Zhang X; Li Y
Anticancer Agents Med Chem; 2020; 20(13):1548-1557. PubMed ID: 32329699
[TBL] [Abstract][Full Text] [Related]
46. Clinical utility of [
Zhao L; Pang Y; Zheng H; Han C; Gu J; Sun L; Wu H; Wu S; Lin Q; Chen H
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3606-3617. PubMed ID: 33792760
[TBL] [Abstract][Full Text] [Related]
47. Development of a Novel PET Tracer [18F]AlF-NOTA-C6 Targeting MMP2 for Tumor Imaging.
Liu Q; Pan D; Cheng C; Zhang D; Zhang A; Wang L; Jiang H; Wang T; Liu H; Xu Y; Yang R; Chen F; Yang M; Zuo C
PLoS One; 2015; 10(11):e0141668. PubMed ID: 26540114
[TBL] [Abstract][Full Text] [Related]
48. Head-to-head intra-individual comparison of biodistribution and tumor uptake of
Giesel FL; Kratochwil C; Schlittenhardt J; Dendl K; Eiber M; Staudinger F; Kessler L; Fendler WP; Lindner T; Koerber SA; Cardinale J; Sennung D; Roehrich M; Debus J; Sathekge M; Haberkorn U; Calais J; Serfling S; Buck AL
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4377-4385. PubMed ID: 34137945
[TBL] [Abstract][Full Text] [Related]
49. Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging.
Zhang N; Pan F; Pan L; Diao W; Su F; Huang R; Yang B; Li Y; Qi Z; Zhang W; Wu X
Front Bioeng Biotechnol; 2023; 11():1167329. PubMed ID: 37057133
[TBL] [Abstract][Full Text] [Related]
50. Pre-clinical study of a TNFR1-targeted
Fu H; Wu H; Zhang X; Huang J; He X; Chen L; Guo W; Guo X; Hao B; Li Y
Amino Acids; 2018 Apr; 50(3-4):409-419. PubMed ID: 29243062
[TBL] [Abstract][Full Text] [Related]
51. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.
Varasteh Z; Aberg O; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Antoni G; Sandström M; Tolmachev V; Orlova A
PLoS One; 2013; 8(12):e81932. PubMed ID: 24312607
[TBL] [Abstract][Full Text] [Related]
52. The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG.
Cui Y; Liu H; Liang S; Zhang C; Cheng W; Hai W; Yin B; Wang D
Oncotarget; 2016 May; 7(19):27243-54. PubMed ID: 27029065
[TBL] [Abstract][Full Text] [Related]
53. FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.
Yang T; Ma L; Hou H; Gao F; Tao W
Front Oncol; 2021; 11():797960. PubMed ID: 35059319
[TBL] [Abstract][Full Text] [Related]
54. One-step radiosynthesis of ¹⁸F-AlF-NOTA-RGD₂ for tumor angiogenesis PET imaging.
Liu S; Liu H; Jiang H; Xu Y; Zhang H; Cheng Z
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1732-41. PubMed ID: 21617974
[TBL] [Abstract][Full Text] [Related]
55. Design and Development of
Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
[TBL] [Abstract][Full Text] [Related]
56. Preparation and Bioevaluation of
Ruan Q; Feng J; Jiang Y; Zhang X; Duan X; Wang Q; Yin G; Xiao D; Zhang J
Mol Pharm; 2022 Jan; 19(1):160-171. PubMed ID: 34904839
[TBL] [Abstract][Full Text] [Related]
57. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
58. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA
Moon ES; Elvas F; Vliegen G; De Lombaerde S; Vangestel C; De Bruycker S; Bracke A; Eppard E; Greifenstein L; Klasen B; Kramer V; Staelens S; De Meester I; Van der Veken P; Rösch F
EJNMMI Radiopharm Chem; 2020 Jul; 5(1):19. PubMed ID: 32728930
[TBL] [Abstract][Full Text] [Related]
59. Radiation Dosimetry and Biodistribution of
Meyer C; Dahlbom M; Lindner T; Vauclin S; Mona C; Slavik R; Czernin J; Haberkorn U; Calais J
J Nucl Med; 2020 Aug; 61(8):1171-1177. PubMed ID: 31836685
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of an [(18)F]AlF-NOTA Analog of Exendin-4 for Imaging of GLP-1 Receptor in Insulinoma.
Kiesewetter DO; Guo N; Guo J; Gao H; Zhu L; Ma Y; Niu G; Chen X
Theranostics; 2012; 2(10):999-1009. PubMed ID: 23139727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
